SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-18-006056
Filing Date
2018-05-07
Accepted
2018-05-07 16:34:04
Documents
59
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20180331x10q.htm 10-Q 763999
2 EXHIBIT 10.1 mrtxex101.htm EX-10.1 533288
3 EXHIBIT 10.2 mirati-amendedandrestatedn.htm EX-10.2 24209
4 EXHIBIT 31.1 mrtx033118ex311.htm EX-31.1 12404
5 EXHIBIT 31.2 mrtx033118ex312.htm EX-31.2 12868
6 EXHIBIT 32.1 mrtx033118ex321.htm EX-32.1 8229
  Complete submission text file 0001628280-18-006056.txt   3830589

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT mrtx-20180331.xml EX-101.INS 654977
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20180331.xsd EX-101.SCH 26921
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20180331_cal.xml EX-101.CAL 47087
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20180331_def.xml EX-101.DEF 66361
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20180331_lab.xml EX-101.LAB 300958
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20180331_pre.xml EX-101.PRE 167496
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 18811712
SIC: 2834 Pharmaceutical Preparations